EU Expects Exemption for Generic Medicines from Trump's Tariffs

London, United Kingdom Jul 22, 2026 ALN: The European Commission said Wednesday that it expects European generic medicines to be exempt from U.S. President Donald Trump’s latest tariffs, arguing that Washington committed to a zero tariff rate with last year’s transatlantic trade deal.

Trump on Tuesday announced a plan to impose a 100 percent tariff on generic drugs starting in August 2028 as part of a bid to bring pharmaceutical production back to the United States. If implemented, the tariff would then jump to 200 percent in 2029, the president said in a social media post. This announcement has raised significant concerns among various stakeholders, particularly in the pharmaceutical sector, where the implications of such tariffs could be profound.

But under the 2025 trade deal struck in Turnberry, Scotland, the U.S. promised to exempt European generic drugs from higher levies. The pact foresees that exports of EU generic pharmaceuticals would only be subjected to the U.S. most-favored-nation tariff rate, a rate imposed on all U.S. partners, effectively 0 percent. This commitment was intended to foster a stable trading environment for pharmaceuticals and ensure that patients in the U.S. have access to affordable medications.

Under the joint statement, “the United States committed to exempting generic medicines from the 15% tariffs; therefore MFN [most-favored-nation] treatment continues to apply, corresponding to a 0% tariff rate,” said the European Commission deputy chief spokesperson Olof Gill. He added that EU innovative drugs continue to be subject to a 15 percent tariff. This distinction between generic and innovative drugs highlights the ongoing debate over drug pricing and accessibility, particularly in the context of rising healthcare costs in the U.S.

“This clearly shows that the EU–U.S. Joint Statement is delivering by preserving stability and predictability, and protecting a key strategic sector from disruption and tariff increases,” Gill stressed. The deal as such is not legally binding, but any breach of its terms would likely unleash tit-for-tat tariff retaliation. This potential for retaliation underscores the fragile nature of international trade agreements and the delicate balance that must be maintained between protecting domestic industries and fostering international cooperation.

Trump’s latest threat comes as his administration is scrambling to rebuild its tariff wall after a legal setback earlier this year, with its temporary 10 percent tariffs due to lapse Friday. The administration has faced challenges in implementing its trade policies, particularly in the pharmaceutical sector, where tariffs could have far-reaching implications for drug availability and pricing. Although Washington insisted that the new probes would not breach the 15 percent threshold enshrined by the transatlantic deal, the EU is still bracing for more investigations, targeting forced labor, excess capacity in the manufacturing sector and possibly also digital services tax. These investigations reflect broader concerns about fair trade practices and the need to address issues that can distort market dynamics.

Drug shortage risks 

The EU generics lobby, Medicines for Europe, said the measures risked triggering “significant medicine shortages across the United States.” Off-patent drugs from Europe “should remain exempt from tariffs under all circumstances” under the Turnberry agreement, the trade group said. The concern over medicine shortages is not unfounded, as generic drugs play a critical role in ensuring that patients have access to affordable treatment options. A disruption in the supply of these medications could have serious consequences for patient health and the overall healthcare system.

Swiss generics manufacturer Sandoz said Wednesday morning it was “too early to assess the potential implications, as further details on the implementation and scope of the measure are still required.” A Sandoz spokesperson added the company would continue dialogue with policymakers on how to improve affordability and access to medicines in the U.S. This ongoing dialogue is essential for navigating the complexities of international trade and ensuring that the needs of patients are prioritized.

Threats to generic medicines increase pressure on the pharmaceutical sector, after the Trump administration threatened new levies on Germany over its drug pricing policies. This broader context of international trade tensions reflects the intricate relationships between countries and the pharmaceutical industry, where pricing practices can lead to disputes that impact not only trade relations but also patient access to essential medications.

Washington alleges that Berlin’s laws result in the U.S. paying a disproportionate share of research and development costs for innovative drugs. U.S. Trade Representative Jamieson Greer said last week that he was also in talks with France over its pricing practices. These discussions indicate a growing scrutiny of international pricing strategies and their impact on the global pharmaceutical landscape.

“The pharmaceutical sector is critically important on both sides of the Atlantic, with highly integrated supply chains, strong investment and research ties, and broadly balanced trade flows. Preserving these links is essential both for patient access and for sustaining innovation,” added Gill, the Commission spokesperson. The interconnectedness of the pharmaceutical sector highlights the need for cooperative approaches to trade and regulation, as disruptions in one area can have cascading effects throughout the industry.

In conclusion, the anticipated tariffs on generic medicines present a complex challenge that intertwines international trade policy, healthcare access, and the sustainability of the pharmaceutical sector. As both the U.S. and EU navigate these challenges, the outcomes will likely have significant implications for patients, healthcare providers, and the broader economy. Stakeholders on both sides will need to engage in constructive dialogue to address these issues and seek solutions that prioritize patient health while also considering the economic realities of the pharmaceutical industry.